Form 4: Director Receives Stock Option for Board Fees

Christina Bray, a Director at BioLargo, Inc., was granted a stock option for services rendered as a board member.

Summary

• Christina Elaine Bray, a Director of BioLargo, Inc., received a stock option grant on June 30, 2026.
• This option is compensation for $18,750 in fees for services provided to the company's board of directors during the most recent completed quarterly period.
• The option was issued under the Issuer's 2024 Equity Incentive Plan.
• The number of shares in the option is calculated by dividing the total fees due by the exercise price of the option.
• The option has an exercise price of $0.1135 per share and an expiration date of June 30, 2036.
• Following the transaction, Bray beneficially owns 1,546,700 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it details a standard director compensation transaction without providing new financial performance data or strategic shifts.

Positives

• Director compensation is being provided through equity, aligning incentives with shareholders.
• The company has a formal equity incentive plan in place for director compensation.
• The option grant is directly tied to services rendered, indicating a clear business purpose.

Negatives

• The filing does not provide details on the company's overall financial health or performance, only a director's compensation.
• The low exercise price of the option ($0.1135) may suggest a low current market valuation for the stock.

Risks

• The value of the stock option is subject to the future performance and market price of BioLargo, Inc. stock.
• If the company's stock price does not increase significantly, the option may not provide substantial value to the director.

Future Outlook

The filing itself is a historical record of a transaction and does not contain forward-looking statements or guidance from the company regarding its future financial performance or strategic direction. The future value of the granted stock option is contingent on the company's future stock price.

Management Comments

• The option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.
• The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

Industry Context

StockSavvy.ai notes that the issuance of stock options as compensation for director fees is a common practice in the biotechnology and technology sectors, particularly for early-stage or growth-oriented companies like BioLargo, Inc. This method aims to conserve cash while aligning director interests with shareholder value.

Corporate Governance

Related Party Transactions

• The stock option grant to Director Christina Bray for board services is a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of stock options dilutes existing share ownership slightly, but also aligns director compensation with potential future stock price appreciation.
• Directors: Christina Bray receives compensation for her services, with the potential for future financial gain if the stock price increases.
• Employees: The filing does not directly impact employees, but the company's compensation structure may influence employee morale and retention.

Next Steps

• Christina Bray may exercise her stock options on or after June 30, 2026, provided the option is still valid and she chooses to do so.
• The company will continue to operate under its 2024 Equity Incentive Plan for future director and employee compensation.

Key Dates

Keywords

Form 4, SEC Filing, Director Compensation, Stock Option, BioLargo Inc., BLGO, Equity Incentive Plan, Beneficial Ownership, Insider Trading